GlycoMantra is a biotechnology company focused on developing innovative therapeutics that address significant unmet medical needs, particularly in the areas of metastatic castration-resistant prostate cancer, NASH liver fibrosis, and type 2 diabetes. The company is leveraging glycobiology, which studies the role of carbohydrates in biological processes, to create novel treatments. Their research emphasizes the importance of galectin-3, a protein that plays a critical role in cancer progression and metastasis by facilitating neo-angiogenesis and influencing cell adhesion, as well as suppressing host immune responses. GlycoMantra aims to develop high-affinity carbohydrate-based drugs that can effectively counteract abnormal protein-carbohydrate interactions that contribute to various diseases.

The company is committed to translational research in glycobiology, focusing on the development of carbohydrate-based therapeutics. Their approach recognizes that the surfaces of animal cells are covered with carbohydrates and proteins, which mediate essential interactions between cells and their extracellular environment. Disruptions in these interactions can lead to diseases such as cancer, fibrosis, and diabetes. By targeting these abnormal interactions, GlycoMantra seeks to create effective treatments that can improve patient outcomes in these challenging medical conditions.

United States

GlycoMantra is a biologics company developing novel therapeutics for unmet medical needs in metastatic castration-resistant prostate cancer, NASH liver disease, and other diseases.

GlycoMantra

Company Details